Menu

Recent Interviews

Ryan Jackson, CEO, Newlox Gold Ventures Corp.

Ryan Jackson
CEO | Newlox Gold Ventures Corp.
60 Laurie Crescent, V7S 1B7 West Vancouver (CAN)

info@newloxgold.com

+1 778 738 0546

Newlox CEO Ryan Jackson on building a green gold producer with a rapid growth trajectory


Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


23. September 2020 | 09:05 CET

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.

time to read: 2 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Tax money accelerates development

The development of medical agents is costly and time-consuming. Politicians and companies are working closely together on research into a vaccine against Covid-19. Social peace is already at stake in many countries, and for this reason, specialized companies must be given financial leeway to get to the goal as quickly as possible: the vaccine. The two German companies BioNTech and CureVac have each received pledges of taxpayers' money in the high three-digit million range with the achievement of milestones.

Strengthening the industry

BioNTech and CureVac offer investors who want to participate in the race for a vaccine with the solid legal and regulatory framework of the European Union and other developed markets. However, it should be noted that the market capitalization is already in the multi-billion range so high expectations have already been priced in. The fight against Covid-19 has brought these companies to the forefront of global competition, which is expected to strengthen the industry for the time after the pandemic, and the experience gained will also be used in other areas of the companies for the development of other products.

Access to patients generates revenue

Anyone afraid of the research and development risk should take a look at Valeo Pharma, as the company focuses on bringing to market products already tried and tested by other biotech companies. The main market for its medical products is Canada. According to its statements, Valeo Pharma can accompany the entire process of handling products. Especially for small researching market participants, specialized companies like Valeo Pharma offer an excellent sales channel. The sales staff are in direct contact with doctors and medical institutions. This is how specific prescription products find their way to the patient.

Marketing authorization enables sales offensive

In the context of the current corona pandemic, Valeo Pharma is working with its partner Ingenew. Ingenew's Hesperco capsules are designed to support the immune system and Valeo Pharma has accompanied the marketing authorization process and is now taking care of the distribution. Pierre Laurin, CEO of Ingenew, explained the importance of the active ingredient in a press release: "(...) Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidate to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)“

Portfolio offers growth potential

Besides Hesperco, Valeo Pharma has eight other products in its portfolio and six more in the pipeline. The latest financing round provides the company with sufficient capital for a sales offensive. The company was able to raise CAD 6.9 million from investors at a share price of CAD 1.20, thus laying the foundation for the future. "(...) The proceeds of this financing will be used to support the launch of several new products in the coming months and to accelerate new growth opportunities," said Steve Saviuk, CEO of Valeo Pharma. With a market capitalization of CAD 75 million, Valeo Pharma costs only a fraction of the market capitalization of BioNTech and CureVac.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

21. October 2020 | 12:42 CET | by Stefan Feulner

BioNTech, Valeo Pharma, Pfizer - Starting signal!

  • Covid-19

Who will make the race for the first approved Corona vaccine? Russia, China, and several North American suppliers are fighting for a place in the sun. The second and third parties should also benefit from the approval, as the demand is enormous among the nearly 8 billion inhabitants of the earth. One thing is clear; the winners of this almost macabre-sounding "Corona contest" will go through the roof. Those who receive late approval or no approval at all risk extinction. Admittedly, the world is looking at the long-awaited miracle cure. But there are easier ways for every individual to protect themselves against viruses.

Read

18. September 2020 | 06:00 CET | by Mario Hose

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.

Read

11. September 2020 | 09:59 CET | by Mario Hose

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.

Read